Clinical trials
ER Positive Breast Cancer clinical trials
Below are recruiting er positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 435 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT04601116RecruitingPhase 3
Atorvastatin for hormone-positive breast cancer to prevent recurrence
This Phase 3 study tests whether taking atorvastatin (a cholesterol-lowering medicine) can improve outcomes for women with estrogen-receptor–positive breast cancer. It may help by affecting cancer-related pathways and reducing risk of recurrence or progression.
AarhusAges 18 years+ - NCT04646759RecruitingPhase 3
Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Guangzhou, GuangdongAges 18–80 - NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
Prato, TuscanyAges Any age - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT04841148RecruitingPhase 2
Avelumab or hydroxychloroquine to target hidden breast cancer
This Phase 2 trial tests whether adding different medicines—either avelumab or hydroxychloroquine, with or without palbociclib—can eliminate dormant “leftover” breast cancer cells. It’s meant for people with hormone-receptor–positive breast cancer who have no visible cancer now, but still have detectable dormant cells in the bone marrow.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT04891068RecruitingPhase 2
Pre-surgery low-dose azacitidine for high-risk early breast cancer
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Chicago, IllinoisAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04921137RecruitingPhase 4
Testing benefits and side effects of hormone therapy in older breast cancer patients
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Edmonton, AlbertaAges 70 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT07366112RecruitingPhase 2
CDK4/6 inhibitor plus hormone therapy before breast cancer surgery
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05020860RecruitingPhase 2
Study how early breast cancer responds on imaging and under a microscope
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Houston, TexasAges 18 years+ - NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05059379RecruitingPhase 3
Different radiation fields after breast cancer surgery
This trial compares two ways of giving radiation to lymph node areas near the collarbone after surgery for invasive breast cancer. It aims to see which radiation approach works better and is safer for preventing cancer returning in these lymph nodes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05063136RecruitingPhase 3
Metronomic capecitabine with hormone therapy after breast cancer
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
Zhengzhou, HenanAges 18–70 - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05159193RecruitingPhase 3
Pre-surgery chemotherapy and antibodies for HER2 breast cancer
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Guandong, GuangdongAges 18–70 - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05205200RecruitingPhase 2
Immune therapy for HR-positive, HER2-negative metastatic breast cancer
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
ShanghaiAges 18–75
Hear when a new ER Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er positive breast cancer?
- Yes. Clin2 currently lists 435 recruiting er positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Node-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.